Chronic Hepatitis B Market Report 2026

The chronic hepatitis b market size has grown steadily in recent years. It will grow from $3.93 billion in 2025 to $4.1 billion in 2026 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to improved hepatitis B screening programs, expansion of antiviral drug availability, rising awareness of liver disease complications, increased use of nucleos(t)ide analogs, establishment of long-term disease monitoring protocols.

The chronic hepatitis b market size is expected to see steady growth in the next few years. It will grow to $4.74 billion in 2030 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to increasing investments in next-generation HBV therapies, rising demand for finite-duration treatment regimens, expansion of therapeutic vaccine development, growing focus on eliminating viral reservoirs, increased global hepatitis elimination initiatives. Major trends in the forecast period include increasing adoption of long-term antiviral therapies, rising development of functional cure approaches, growing focus on early disease detection and monitoring, expansion of immune-modulating treatment strategies, enhanced patient adherence programs.

The high prevalence of chronic hepatitis B infection is expected to drive the growth of the chronic hepatitis B virus market in the coming years. Hepatitis B is a liver infection caused by the hepatitis B virus (HBV) and can be prevented through vaccination. Rising hepatitis B infection rates are attributed to several factors, especially in low- and middle-income countries, where limited vaccination coverage leads to higher transmission as large segments of the population remain unprotected. Increasing infection rates are likely to boost demand for diagnostic testing and treatment options. For example, in June 2024, a report from the Centers for Disease Control and Prevention (CDC), a US-based government agency, stated that increasing global hepatitis B vaccination coverage to 90% and treatment access to 80% could prevent 26 million new infections and 9 million hepatitis B-related deaths between 2022 and 2050. In 2022 alone, 1.2 million new hepatitis B virus (HBV) infections were reported. Therefore, the high prevalence of hepatitis B infection is contributing to the growth of the chronic hepatitis B virus market.

Major companies in the chronic hepatitis B market are concentrating on technological progress, including the development of novel antiviral therapies. These innovative antiviral treatments are designed to target viral infections, including drug-resistant strains, by inhibiting viral replication and leveraging advanced delivery mechanisms, with multiple candidates undergoing clinical trials to assess safety and efficacy, such as bepirovirsen for chronic hepatitis B. For instance, in February 2024, GSK plc, a UK-based multinational pharmaceutical and biotechnology company engaged in the research, development, manufacturing, and commercialization of healthcare products, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for bepirovirsen, an investigational antisense oligonucleotide (ASO) intended for the treatment of chronic hepatitis B (CHB). Bepirovirsen is designed to target and degrade hepatitis B virus (HBV) RNA, which may enable the immune system to regain control of the infection. The therapy demonstrated encouraging outcomes in Phase IIb clinical trials, including the B-Clear and B-Sure studies, where it showed effectiveness in reducing hepatitis B surface antigen (HBsAg) levels and achieving sustained viral suppression.

In November 2023, GSK plc, a UK-based pharmaceutical company, acquired exclusive rights to a hepatitis B therapy from Janssen Pharmaceuticals for $1 billion. Through the acquisition of rights to JNJ-3989, also known as ARO-HBV, an antisense oligonucleotide drug, GSK aims to broaden its treatment portfolio and reinforce its position in the chronic hepatitis B market by adding a potentially high-value therapy. Janssen Pharmaceuticals, a Belgium-based subsidiary of Johnson & Johnson, focuses on developing treatments for a range of serious and complex conditions, including infectious diseases such as chronic hepatitis B.

Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals.

North America was the largest region in the chronic hepatitis B market in 2025. The regions covered in the chronic hepatitis b market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic hepatitis b market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the chronic hepatitis B market by increasing costs of imported antiviral drug ingredients, biologics, diagnostic reagents, and specialized manufacturing inputs. Regions such as North America and Europe are affected due to reliance on globally sourced active compounds, while Asia-Pacific faces cost pressures on large-scale antiviral production and exports. These tariffs are elevating treatment costs and impacting long-term therapy affordability. At the same time, they are encouraging domestic pharmaceutical manufacturing, regional API synthesis, and strategic partnerships to strengthen antiviral supply chains.

The chronic hepatitis b market research report is one of a series of new reports that provides chronic hepatitis b market statistics, including chronic hepatitis b industry global market size, regional shares, competitors with a chronic hepatitis b market share, detailed chronic hepatitis b market segments, market trends and opportunities, and any further data you may need to thrive in the chronic hepatitis b industry. This chronic hepatitis b market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic hepatitis B is a prolonged infection caused by the hepatitis B virus (HBV) that persists for more than six months and may result in serious liver damage, liver failure, or liver cancer. It often remains without symptoms for many years but can be identified through blood testing and managed with antiviral drugs and routine monitoring.

The primary drug categories used in chronic hepatitis B treatment include antivirals and immunomodulators. Antivirals are medicines developed to suppress viral growth and replication, helping to manage chronic hepatitis B by lowering the viral load in the liver and slowing the progression of liver damage. The gender categories include male and female, while the distribution channels comprise hospital pharmacies, drug stores and retail pharmacies, and online providers.

The chronic hepatitis B market consists of revenues earned by entities by providing services such as diagnostic testing, treatments, liver function monitoring, patient education, and support programs.The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic hepatitis B market also includes sales of medications, interferons, liver transplant medications, diagnostic kits, liver biopsy equipment, and HBV vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.